David Samadi is a prominent medical practitioner who has operated patients in about 40 countries around the world. On November 13, 2017, he shared his experience with Interview.net. When asked what he does for a living, Dr. Samadi said he had developed a unique robotic procedure he uses to diagnose and treat prostate cancer. He said the process is essential because it not only improves the results but also prevents various adverse effects.Dr. David Samadi said that since he was a small boy, he aspired to be a doctor to help other people. However, the development of robotic surgery equipment played an important role in influencing him to join the profession. He made tremendous career advancements after learning about the laparoscopic technology in France.
Challenges and How He Overcomes Them
Dr. David Samadi added that in his early years, he was frustrated as he worked in a hospital that employed slow processes in the management of patients. He only overcame this by accepting the process and discovering that it produced desirable results. While working at hospital and university, he said the positive results help him overcome the existing challenges in those occupations.
How He Remains Productive
To enhance his productivity, Dr. David Samadi has a daily schedule that he follows throughout the year. His typical day starts at 5 a.m. when he wakes up. He gets to his office at around 6 a.m. and performs medical operations until in the afternoon when he spends the rest of the time talking with patients. His advice to fellow professionals is that they should be proud of their potential, success, and positive traits.
Who is Dr. David Samadi?
Dr. David Samadi is a medical practitioner who specializes in using robotic surgery in the treatment of prostate cancer. He does not only treat the prostate like what most of the other doctors do but help the patients have a future that is cancer free.
Upon leaving Iran after the 1979 Revolution, Dr. David Samadi continued his education in London and Belgium. When he went to the United States, he joined Roslyn High School. He joined Stony Brook University where he graduated with a degree in biochemistry and M.D. He continued with his urological training at Montefiore Medical Center.
Dr. David Samadi worked at Columbia Presbyterian in New York between 2002 and 2007 as the director of laparoscopic surgery. He then joined Mount Sinai Medical Center as the Chief of Robotic Surgery and then as the Vice Chair of Urology until 2013. Besides, he has worked with Fox News Channel.
The American Institute of Architects has been the champions of the architecture field. They have protected the licenses of the architects through the provision of various resources. The American Institute of Architects was established in 1857 by 13 architects has grown to be the home of hundreds of architects. Presently, it has more than 90,000 architects who are certified and licensed. The American Institute of Architects (AIA) is based in Washington, USA.
AIA provides various services to members and allied partners. They provide education, government advocacy, public outreach as well as community development practices in their area of focus. AIA works jointly with the qualified team of design and construction in shaping and adding value to the construction sector. The company has a strategic market scheme that they use to market their member architects.
Moreover, they have been providing members and associate architects with web-based resources. The company believes in the future of the architecture industry, and it is committed to protecting its professionals. They have annual conference meeting for the architects, a forum that they use to discuss and share new ideas and address problems they are facing in their field. The company has come up with an excellence design where the most performing professionals get rewarded through award program. The aspect of establishing the plan is to motivate the developing architects. AIA has been sponsoring education systems teaching architecture and design.
The American Institute of Architects has created a top-notch record in handling the clients in their line of duty. The professions stick to the company`s code of ethics and ensure they perform their roles diligently. The success of every business requires a workforce behind it. Therefore AIA has over 200 board of directors who relentlessly are committed to their work. Robert Ivy serves as the CEO of the American Institute of Architects. He is the voice of the architects and the future of the architecture.
After the investigation, he initiated on the future of architecture and the role of the professional architects to the society he made the company realize the economic, social and political challenges facing them. Robert Ivy advice his friends and architects to think beyond their professional life. Ivy believes that architecture affects the public health. He has set up a design to improve public health which includes digital programs and community planning. Robert has been in the architectural field for years, and he is aiming at helping architects meet their dreams. Watch on https://www.youtube.com/user/AIANational
Amicus Therapeutics Inc. is an international biotechnology company that is at the forefront of advancing therapies that aims at treating devastating rare and orphan diseases. Amicus Therapeutics became a public company in 2007 under FOLD which is a NASDAQ trading symbol. Prior to going public, the company was being funded by several venture capital firms such as Radius Ventures and Canaan Partners among others.
Amicus Therapeutics specializes in disorders collectively known as lysosomal storage disorders. The company products are largely based on the Chaperone-Advanced Replacement Therapy (CHART) platform which has concentrated on the development of enzyme replacement therapies (ERTs). Amicus in 2014 was noted as one of the companies with the broadest portfolio of small molecule also known as pharmacological chaperones in the Pharmaceutical industry.
Amicus lead product is the Migalastat which is a personalized late-stage development medicine that helps treat individuals who have Fabry disease from their genetic diagnosis. Another product of Amicus is the SD-101 which is also a late stage development product that provides therapy for Epidermolysis Bullosa (EB) which is a rare genetic connective tissue disorder (http://alivenewspaper.com/2017/09/amicus-therapeutics-fabry-disease-treatment/). Currently, Amicus is leveraging its biologics program and the CHART platform technologies to create a novel Enzyme Replacement Therapy ERT product to help in the diagnosis of Fabry disease, Pompe disease including other Lysosomal Storage Disorders. Amicus lead biologics program is the ATB200/AT2221. The program is a uniquely engineered Pompe disease ERT that will have to be administered together with a pharmacological chaperone.
Amicus Therapeutics has received many grants and donations to help it in conducting researches of advancing the Pharmacological Chaperone Technology. In 2010 Amicus received a grant of 500,000 dollars from The Michael J. Fox Foundation to help advance studies and research in collaboration with David Geffen School of Medicine at UCLA. Also the same year the company received another grant of over 200,000 dollars from the Alzheimers Drug Discovery Foundation. The grant was meant to support the Pre-clinical work together with the Icahn School of Medicine at Mount Sinai under the directive of Alzheimer Disease Research Center.
Amicus Therapeutics has been involved in a couple of major acquisition, and in 2013 the company acquired Callidus Biopharma Company which was one of its competitors. This was a significant move for the company as it gave them the rights to the enzyme replacement therapy treatment of Pompe disease.
More on MarketWatch